NVAX:NGS-Novavax Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 14

Change

0.00 (0.00)%

Market Cap

USD 0.34B

Volume

0.02B

Analyst Target

USD 227.60
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+8.81 (+0.85%)

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

+1.39 (+0.30%)

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

+1.84 (+0.67%)

USD 35.01B
ARGX argenx NV ADR

-24.43 (-4.45%)

USD 32.83B
MRNA Moderna Inc

+0.29 (+0.46%)

USD 25.25B
BGNE BeiGene Ltd

+5.81 (+2.81%)

USD 22.45B
SMMT Summit Therapeutics PLC

+0.17 (+0.75%)

USD 17.92B
RPRX Royalty Pharma Plc

+0.54 (+1.95%)

USD 16.34B
UTHR United Therapeutics Corporatio..

-1.79 (-0.50%)

USD 15.71B
PCVX Vaxcyte Inc

-2.02 (-1.78%)

USD 14.50B

ETFs Containing NVAX

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 191.67% 98% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 191.67% 98% N/A 98% N/A
Trailing 12 Months  
Capital Gain 108.96% 93% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 108.96% 93% A 96% N/A
Trailing 5 Years  
Capital Gain 149.11% 87% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 149.11% 87% B+ 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 457.32% 96% N/A 98% N/A
Dividend Return 457.32% 96% N/A 98% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 987.45% 7% C- 3% F
Risk Adjusted Return 46.31% 92% A 77% C+
Market Capitalization 0.34B 89% A- 80% B-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 12.89 38% 61%
Price/Book Ratio 49.52 3% 2%
Price / Cash Flow Ratio -2.83 56% 71%
Price/Free Cash Flow Ratio -0.53 38% 56%
Management Effectiveness  
Return on Equity -898.20% 10% 4%
Return on Invested Capital 120.60% 94% 97%
Return on Assets -16.32% 79% 28%
Debt to Equity Ratio -23.44% 80% 90%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector